Alpa Laboratories Limited files SEBI Takeover Disclosure under Regulation 31(4)
The disclosure was filed with the NSE (CCDATA portal) on 8 June 2026 per the timestamp on the archived PDF. Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011, any person acquiring 25% or more of a target's equity (or voting rights) must make a public announcement and file detailed disclosures. Regulation 31(4) requires the acquirer to furnish the disclosure to the target and exchanges within the statutory timeline. The pharmaceutical company Alpa Laboratories is the subject of this transaction.
Why it mattersA Regulation 31(4) disclosure triggers mandatory open offer requirements if acquisition crosses the 25% threshold; confirm the acquirer identity and shareholding post-transaction to assess offer obligations and exemption eligibility (e.g., preferential allotment, acquisition from promoter, or exemption under regulation 10).
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Alpa Laboratories Limited Regulation 31(4) Disclosure · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026